Skip to main content

Table 3 Medical diagnoses of CVD after 4 years follow-up

From: Cardiovascular disease in Alpha 1 antitrypsin deficiency: an observational study assessing the role of neutrophil proteinase activity and the suitability of validated screening tools

 

AATD

Non-AATD COPD

Healthy Controls

CVD

Yes

No

Yes

No

Yes

No

N

23

146

18

23

7

39

Age

61 (57–68)*$

56 (48–64)

74.0 (68–76)

70 (67–77)

69 (49–76)

69 (61–76)

PYH

10.5 (1.1–28.0)$

11.4 (15–20.8)

41.5 (36.3–55.0)

43.0 (26.0–51.0)

27.5 (19.7–32.5)

20.5 (10.5–42.3)

aPWV

11.1 (9.9–12.8)*

8.8 (8.0–9.8)

11.4 (10.1–12.6)*

9.7 (8.4–11.0)

10.5 (8.9–11.7)

8.6 (7.22–11.8)

QRISK2®

19.4 (8.1–25.0)*$

9.5 (4.2–13.8)

31.8 (26.0–37.2)*

18.5 (14.9–25.1)

33.9 (28.2–35.3)*

16.9 (6.1–24.2)

  1. Medical notes of all participants were reviewed 4 years after baseline visit. Diagnoses of CVD was physician confirmed. CVD included angina, a myocardial infarction or stroke. Numbers exclude those with a diagnosis of CVD at baseline. All data is presented as median with IQR apart from numbers, which are absolute numbers
  2. *Statistically different from same patient group without CVD
  3. $AATD statistically different from non-AATD COPD and HC when all patients with CVD were compared
  4. PYH = pack year history